Chiasma Inc (NASDAQ:CHMA) – Cantor Fitzgerald upped their FY2019 earnings estimates for Chiasma in a note issued to investors on Wednesday, November 6th. Cantor Fitzgerald analyst B. Folkes now anticipates that the biotechnology company will post earnings of ($1.08) per share for the year, up from their prior forecast of ($1.09). Cantor Fitzgerald has a “Buy” rating and a $18.00 price target on the stock.
Several other research analysts have also commented on CHMA. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Chiasma in a report on Thursday. Brookline Capital Management restated a “buy” rating on shares of Chiasma in a report on Wednesday, July 24th. ValuEngine lowered shares of Chiasma from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Piper Jaffray Companies initiated coverage on shares of Chiasma in a report on Wednesday, July 31st. They issued an “overweight” rating and a $11.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Chiasma from a “buy” rating to a “hold” rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Chiasma currently has a consensus rating of “Buy” and a consensus target price of $12.30.
NASDAQ CHMA traded down $0.09 during trading on Friday, hitting $5.26. The company had a trading volume of 13,516 shares, compared to its average volume of 159,114. Chiasma has a one year low of $2.11 and a one year high of $9.25. The company has a market cap of $225.72 million, a price-to-earnings ratio of -4.11 and a beta of 1.19. The company’s fifty day moving average is $5.14 and its 200-day moving average is $5.95.
Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.01.
Institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new position in shares of Chiasma during the third quarter worth $53,000. Tower Research Capital LLC TRC grew its stake in shares of Chiasma by 461.4% in the third quarter. Tower Research Capital LLC TRC now owns 14,938 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 12,277 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Chiasma in the third quarter valued at about $83,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Chiasma in the second quarter valued at about $100,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Chiasma by 35.4% in the second quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 3,722 shares in the last quarter. Hedge funds and other institutional investors own 53.00% of the company’s stock.
In related news, Director Roni Mamluk sold 10,000 shares of Chiasma stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $4.94, for a total value of $49,400.00. Following the sale, the director now directly owns 10,000 shares in the company, valued at $49,400. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Scott Minick purchased 9,818 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average price of $5.19 per share, for a total transaction of $50,955.42. Following the completion of the purchase, the director now owns 62,531 shares of the company’s stock, valued at $324,535.89. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 17,268 shares of company stock valued at $96,823. 8.30% of the stock is owned by company insiders.
Chiasma Company Profile
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Further Reading: What are the benefits of a balanced fund?
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.